title: Discussion of modifying stage IV gastric cancer based on Borrmann classification.
abstract: This study aims to investigate the prognostic significance of reclassification of stage IV gastric cancers in conjunction with Borrmann type. A total of 1,673 gastric cancer patients who received a gastrectomy between 1980 and 2003 were retrospectively evaluated. Of the patients, 244 (14.58 %), 344 (20.56 %), 589 (35.21 %), and 496 (29.65 %) had stage I, II, III, and IV cancers, respectively. After Cox regression analysis, Borrmann type was identified to be the independent prognostic factor in stage IV gastric cancer. The disease-specific postoperative survival of patients with Borrmann I, II, and III tumors was clearly distinguished by TNM classification system (P<0.05), while it failed to classify Borrmann IV tumors (P=0.147). Interestingly, the disease-specific postoperative survival of stage IV patients with Borrmann IV tumors (group 1) was significantly poor than the cases with stage IV but not Borrmann IV tumors (group 2), as well as the patients with Borrmann IV while not included in stage IV tumors (group 3) (P=0.022 and P=0.000, respectively). Meanwhile, the disease-specific postoperative survival was not observed as significantly different between group 2 and group 3 (P=0.063); furthermore, group 2+3 had a better prognosis than group 1 (introduced stage IVa vs. stage IVb; P=0.006). Reclassification of stage IV through combining the present TNM classification system with Borrmann type may more accurately predict the prognosis of patients.
authors: Department of General Surgery, The 210th Hospital of PLA, Dalian, 116021, China.
authors: Bin
authors: B
authors: Yang
authors: Guoqiang
authors: G
authors: Wu
authors: Xiaochen
authors: X
authors: Wang
authors: Xuefeng
authors: X
authors: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000145:classification* / Q000401:mortality / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000145:classification* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
references: Isr Med Assoc J. 2009 Feb;11(2):98-102
references: 19432038
references: World J Surg. 2005 Jan;29(1):58-65
references: 15599744
references: Br J Surg. 2009 Apr;96(4):398-404
references: 19283740
references: J Clin Oncol. 2009 Apr 20;27(12):1956-62
references: 19273696
references: J Surg Oncol. 2009 May 1;99(6):324-8
references: 19204941
references: Ann Surg. 2009 May;249(5):768-75
references: 19387327
references: Hepatogastroenterology. 2002 May-Jun;49(45):874-7
references: 12064011
references: Dig Surg. 2002;19(5):333-9
references: 12435900
references: ANZ J Surg. 2002 Oct;72(10):739-42
references: 12534387
references: J Clin Oncol. 2007 Jul 1;25(19):2702-8
references: 17602075
references: J Clin Oncol. 2009 Feb 20;27(6):851-6
references: 19139439
references: J Surg Res. 2005 Apr;124(2):225-36
references: 15820252
references: Hepatogastroenterology. 2008 Nov-Dec;55(88):2269-72
references: 19260520
references: J Clin Oncol. 2005 Oct 1;23(28):7114-24
references: 16192595
references: J Surg Oncol. 2012 Jan;105(1):26-30
references: 21761411
references: Lancet Oncol. 2004 Sep;5(9):519
references: 15384209
references: Gastric Cancer. 2008;11(2):111-8
references: 18595018
references: Arch Surg. 2009 Jan;144(1):38-45; discussion 45
references: 19153323
references: Eur J Surg Oncol. 2009 May;35(5):486-91
references: 19171450
references: Ann Surg Oncol. 2009 Jan;16(1):61-7
references: 18998065
references: J Gastrointest Surg. 2008 Aug;12(8):1364-9
references: 18516653
references: J Clin Oncol. 2006 May 10;24(14):2188-96
references: 16682738
references: Gastric Cancer. 1998 Dec;1(1):10-24
references: 11957040